The European Parliament’s proposed changes to the Commission’s draft text for revising the Classification, Labeling and Packaging (CLP) regulation, specifically concerning the classification of renewable substances of botanical origin, “are essential to supporting the future of the natural ingredients used in cosmetics and fragrances,” IFRA and Cosmetics Europe say.
The fragrance and cosmetics industries’ nightmares of vanishing lavender fields and natural ingredient depletion under the European Green Deal may be receding after Parliament adopted its position on 4 October regarding EU revision of the Classification, Labeling and Packaging (CLP) regulation.
Parliament will head into trilogues with the Council and European Commission with a position on substances containing more than...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
